Comparative Review of Ulcerative Colitis/Inflammatory Bowel Disease Therapeutics Coverage Across 3 Major Health Plans
How Are Major Health Plans Managing Access to UC Therapies?
The treatment landscape for ulcerative colitis (UC) continues to evolve rapidly, with new biologics, oral therapies, biosimilars, and novel mechanisms of action reshaping treatment decisions. As therapeutic options expand, payer strategies are becoming increasingly complex—making it more important than ever to understand how health plans are managing formulary access.
In this exclusive Formulary Frontlines® report, First Report Managed Care compares formulary coverage across Blue Cross Blue Shield FEP Blue Standard, Cigna Healthcare Standard 3-Tier, and UnitedHealthcare to identify differences in coverage, tier placement, prior authorization requirements, specialty pharmacy management, dispensing limits, and quantity limits across today's leading UC therapies.
Key Takeaways
- Advanced therapies see the greatest variation in payer coverage. While conventional treatments such as aminosalicylates and corticosteroids remain broadly accessible, biologics and targeted oral therapies are managed very differently across health plans.
- Cigna generally provides the most favorable access to advanced UC therapies, frequently placing biologics and targeted oral agents on lower formulary tiers while managing utilization through prior authorization, specialty pharmacy requirements, and quantity limits.
- UnitedHealthcare applies the most restrictive utilization management, often assigning therapies to higher specialty tiers and incorporating dispensing limits in addition to prior authorization and quantity limits.
- Blue Cross Blue Shield takes a balanced approach, maintaining broad therapeutic coverage while placing many advanced therapies on higher specialty tiers with prior authorization requirements.
- Utilization management—not coverage alone—is becoming the key differentiator. As additional therapies and biosimilars enter the market, access decisions are increasingly shaped by tier placement, specialty pharmacy requirements, and utilization controls rather than whether a therapy is included on formulary.
Download the full report to gain a comprehensive understanding of formulary positioning, utilization management strategies, and payer trends influencing access to ulcerative colitis therapies.
